P 2202
Alternative Names: P2202Latest Information Update: 11 Jun 2015
At a glance
- Originator Eli Lilly and Company
- Developer Piramal Enterprises
- Class Antihyperglycaemics; Antihyperlipidaemics; Small molecules
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 01 Dec 2013 Piramal Life Sciences completes a phase I pharmacokinetics trial (healthy volunteers) in India (CTRI2010-091-002992)
- 03 Jun 2013 Piramal Healthcare terminates a phase II trial in Type 2 diabetes mellitus in Canada and India (NCT01674348)
- 25 Feb 2013 Piramal Healthcare completes enrolment in its phase I trial in healthy volunteers in India